Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06512259 · ClinicalTrials.gov registry record
AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction
A clinical trial of Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy, sponsored by AlloSource.
- Recruiting
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT06512259: Recruiting study of Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy, sponsored by AlloSource.
NCT06512259 is a study of Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy that is actively recruiting participants, run by AlloSource. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06512259, a study of Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy, is actively recruiting participants, sponsored by AlloSource.
- RECRUITING
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
Primary Outcome
The primary objective is to obtain descriptive data and surgical intervention and post operative surgical outcome data on AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
Conditions Studied
Interventions
- OTHER AlloMend® Acellular Dermal Matrix allograft
Study Locations (1)
Illinois
- Alan H. Chen Surgical Associates, PC - Joliet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2023-10-19 |
| Est. Completion | 2026-12-31 |
What NCT06512259 shows while recruiting
NCT06512259 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy appearing as the primary indexed condition, and to 1 intervention - of which AlloMend® Acellular Dermal Matrix allograft is the first listed.
NCT06512259 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06512259 about?
NCT06512259 is a clinical study titled "AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction". This is a single-center, retrospective study which will be used to describe and evaluate the effectiveness of AlloMend® Acellular Dermal Matrix allograft for patients that have undergone Pre-Pectoral Breast Reconstruction surgery following a single or double mastectomy.
What is the current status of trial NCT06512259?
This trial is currently recruiting. The enrollment target is 200 participants. The study started on 2023-10-19. Estimated completion is 2026-12-31.
What conditions does trial NCT06512259 study?
This clinical trial studies the following conditions: Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy.
What interventions are being tested in trial NCT06512259?
The interventions under investigation include: AlloMend® Acellular Dermal Matrix allograft (OTHER).
Who is sponsoring clinical trial NCT06512259?
This trial is sponsored by AlloSource, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06512259 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI